Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
Morita Y, Yagi Y, Kanemasa Y, Sasaki Y, Ishimine K, Hayashi Y, Mino M, Ohigashi A, Tamura T, Nakamura S, Okuya T, Shimizuguchi T, Shingai N, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Doki N, Okuyama Y, Ohashi K, Shimoyama T. Morita Y, et al. Among authors: shimizuguchi t. Rinsho Ketsueki. 2023;64(7):586-595. doi: 10.11406/rinketsu.64.586. Rinsho Ketsueki. 2023. PMID: 37544717 Japanese.
Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
Yagi Y, Kanemasa Y, Ohigashi A, Morita Y, Tamura T, Nakamura S, Otsuka Y, Kishida Y, Kageyama A, Shimizuguchi T, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Doki N, Okuyama Y, Omuro Y, Shimoyama T. Yagi Y, et al. Among authors: shimizuguchi t. Medicine (Baltimore). 2021 Nov 5;100(44):e27733. doi: 10.1097/MD.0000000000027733. Medicine (Baltimore). 2021. PMID: 34871273 Free PMC article.
[Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience].
Yagi Y, Kanemasa Y, Sasaki Y, Hayashi Y, Mino M, Kato C, Sakai S, Ohigashi A, Kanbara Y, Morita Y, Tamura T, Atsuta Y, Konuma R, Nakamura S, Wada A, Okuya T, Kageyama A, Murakami D, Nakashima S, Uchibori Y, Onai D, Hamamura A, Nishijima A, Omuro Y, Shingai N, Shimizuguchi T, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Ohashi K, Doki N, Okuyama Y, Shimoyama T. Yagi Y, et al. Among authors: shimizuguchi t. Rinsho Ketsueki. 2022;63(10):1363-1372. doi: 10.11406/rinketsu.63.1363. Rinsho Ketsueki. 2022. PMID: 36351641 Japanese.
Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.
Yagi Y, Kanemasa Y, Sasaki Y, Sei M, Matsuo T, Ishimine K, Hayashi Y, Mino M, Ohigashi A, Morita Y, Tamura T, Nakamura S, Okuya T, Shimizuguchi T, Shingai N, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Doki N, Okuyama Y, Shimoyama T. Yagi Y, et al. Among authors: shimizuguchi t. Cancer Med. 2023 Sep;12(17):17808-17821. doi: 10.1002/cam4.6412. Epub 2023 Aug 28. Cancer Med. 2023. PMID: 37635630 Free PMC article.
Determining the recommended dose of stereotactic body radiotherapy boost in patients with cervical cancer who are unsuitable for intracavitary brachytherapy: a phase I dose-escalation study.
Ito K, Kito S, Nakajima Y, Shimizuguchi T, Ogawa H, Nihei K, Tanaka H, Kino N, Yasugi T, Karasawa K. Ito K, et al. Among authors: shimizuguchi t. Jpn J Clin Oncol. 2019 Sep 1;49(9):856-861. doi: 10.1093/jjco/hyz074. Jpn J Clin Oncol. 2019. PMID: 31112278 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 37785079
Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
Karasawa K, Hayakawa S, Machitori Y, Shibata Y, Ogawa H, Ito K, Shimizuguchi T, Kawamoto T, Nihei K. Karasawa K, et al. Among authors: shimizuguchi t. Technol Cancer Res Treat. 2018 Jan 1;17:1533033818806318. doi: 10.1177/1533033818806318. Technol Cancer Res Treat. 2018. PMID: 30317929 Free PMC article.
27 results